Re : Leclercq et al.: Anti-tumor necrosis factor-α versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French Uveitis Network (Ophthalmology. 2022;129:520-529)
| Errataetall: |
CommentOn: Ophthalmology. 2022 May;129(5):520-529. - PMID 34793830 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:129 |
|---|---|
| Enthalten in: |
Ophthalmology - 129(2022), 7 vom: 01. Juli, Seite e77 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pépin, François [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 27.06.2022 Date Revised 15.07.2022 published: Print-Electronic CommentOn: Ophthalmology. 2022 May;129(5):520-529. - PMID 34793830 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ophtha.2022.02.019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338766529 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338766529 | ||
| 003 | DE-627 | ||
| 005 | 20231226001416.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ophtha.2022.02.019 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1129.xml |
| 035 | |a (DE-627)NLM338766529 | ||
| 035 | |a (NLM)35346510 | ||
| 035 | |a (PII)S0161-6420(22)00158-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pépin, François |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Re |b Leclercq et al.: Anti-tumor necrosis factor-α versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French Uveitis Network (Ophthalmology. 2022;129:520-529) |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.06.2022 | ||
| 500 | |a Date Revised 15.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Ophthalmology. 2022 May;129(5):520-529. - PMID 34793830 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Niederer, Rachael L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ophthalmology |d 1993 |g 129(2022), 7 vom: 01. Juli, Seite e77 |w (DE-627)NLM000457019 |x 1549-4713 |7 nnns |
| 773 | 1 | 8 | |g volume:129 |g year:2022 |g number:7 |g day:01 |g month:07 |g pages:e77 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ophtha.2022.02.019 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 129 |j 2022 |e 7 |b 01 |c 07 |h e77 | ||